+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07052669

Phase III Study Comparing Hypofractionated and Conventional Chemoradiotherapy Followed by Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer

Led by Sun Yat-sen University · Updated on 2025-07-23

311

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating treatments for locally advanced non-small cell lung cancer LANSCLC, focusing on comparing two radiotherapy approaches combined with immunotherapy. This phase III randomized controlled trial evaluates whether hypofractionated chemoradiotherapy followed by consolidative immunotherapy is as effective and safe as conventional fractionated chemoradiotherapy followed by consolidative immunotherapy in patients with this condition. Participants are randomly assigned in a 21 ratio to either receive hypofractionated chemoradiotherapy or conventional fractionated chemoradiotherapy. Both groups receive consolidative immunotherapy for up to 12 months after completing chemoradiotherapy. The hypofractionated group undergoes a split-course radiotherapy with specific dosing schedules and intervals, while the conventional group receives a standard fractionated radiotherapy dose. Concurrent chemotherapy with paclitaxel plus platinum-based or pemetrexed plus platinum-based agents is given during radiotherapy. Throughout the study, participants undergo assessments of tumor response, toxicity, and quality of life at defined intervals. Researchers monitor progression-free survival over two years as the primary outcome, along with secondary outcomes including response rate, overall survival, failure patterns, adverse events, and quality of life using specific questionnaires. Safety is closely observed for one year after treatment, and the total study duration extends up to the end date in 2029, with structured follow-ups and evaluations throughout.

CONDITIONS

Brief Title

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

Research Team

B

Bo Qiu, Professor

H

Hui Liu, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here